Intuitive Surgical part recall hits FDA Class II; Mindray Medical re-elects two board members;

@FierceMedDev: Investors propel St. Jude Medical to new heights over 2013 rebound. Article | Follow @FierceMedDev

@MarkHFierce: So, how many device companies will go for FDA/CMS parallel review now that the pilot program has been extended? More | Follow @MarkHFierce

@MichaelGFierce: Synapse collects state-funded $2.4M for next-gen diaphragm pacing device. Item | Follow @MichaelGFierce

@GalenMoore: ICYMI: Despite tax hike, Medtronic's money still flies to Puerto Rico. Story | Follow @GalenMoore

> China's Mindray Medical ($MR) has re-elected two board members, the medical device giant disclosed. Item

> The FDA has slapped Class II status on a recall of thousands of components used in Intuitive Surgical's ($ISRG) da Vinci surgical robot. Story

> Covidien ($COV) plans to release its fiscal 2014 first-quarter results on Jan. 24, 2014. Item

> Medicina, a U.K. device outfit that makes syringes, tubes and pumps for nutrition delivery, pulled in $9.8 million in new funding. Story

> Blaze Bioscience is launching a clinical trial of a new injectable imaging agent for various kinds of skin cancer. Item

Biotech News

@FierceBiotech: Alimera, pSivida skyrocket as they give the thrice-rejected Iluvien another go. More | Follow @FierceBiotech

@JohnCFierce: Another day, another positive PhIII study for AMG 145 (PCSK9). Release | Follow @JohnCFierce

@DamianFierce: GSK and Theravance score another FDA approval with Anoro, a novel COPD combo therapy. News | Follow @DamianFierce

@EmilyMFierce: BRAIN Initiative announces 6 funding opportunities for biomedical researchers. More from FierceBiotech Research | Follow @EmilyMFierce

> Alimera, pSivida skyrocket as they give the thrice-rejected Iluvien another go. Article

> Vertex's Kalydeco flunks a Phase III for cystic fibrosis. Story

> AstraZeneca will pay up to $4.1B for Bristol's share of their diabetes pact. More

> Bayer bags Algeta's cancer drug portfolio for $2.9B. News

Pharma News

@FiercePharma: South Africa's top business daily accuses its state pension fund of protectionism vs. a $1.2B deal with Chile's CFR Pharma. More from Reuters | Follow @FiercePharma

@EricPFierce: AstraZeneca gets former Amylin plant & Bristol-Myers Ohio plant in breakup of diabetes venture. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: As GSK hails its FDA nod for Anoro, a Novartis Advair knockoff prepares for its close-up. Story | Follow @CarlyHFierce

> With a sweetened $2.9B bid, Bayer nabs its Xofigo partner, Algeta. Report

> Bristol-Myers bails out of 'Diabetes Inc.' in $4.1B sell-out to AstraZeneca. Story

> GlaxoSmithKline scores FDA nod for blockbuster COPD hopeful Anoro Ellipta. News

> Raised eyebrows at patient charity spotlight copay assistance debate. More

Pharma Manufacturing News

> Hacked off: Congress members, PhRMA urge an outside audit of the FDA data breach. Story

> Regeneron will invest $300M, hire 300 in its revamp of a Dell plant in Ireland. More

> The FDA and EU members will share some inspection duties. News

> AstraZeneca will take over 2 U.S. plants in its $4.1B diabetes drug transfer. Report

> CEO Nakayama says Daiichi Sankyo is helping Ranbaxy deal with the FDA's concerns. Article

> FDA puts veterinary drugs from banned Wockhardt plants on a leash. Item

Vaccines News

> Schulman leaves Pfizer weeks before start date of new top vaccine job. More

> CDC: Vaccines prevented 6M cases of flu, 79,000 hospitalizations last year. News

> Moderate alcohol consumption acts as vaccine adjuvant in monkeys. Article

> Physician failings raise doubts about the potency of U.K. vaccines. Story

> Agenus stock jumps on Phase II brain cancer vaccine data. Piece

> California calls for unapproved Bexsero to stop its meningitis outbreak. Item

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.